|
|
|
| Research progress of common muscle factors in non-alcoholic fatty liver disease |
| ZHANG Xin1 ZHAO Xinyan1 YANG Fan1 WEI Xiaoguo2 |
1.The First Clinical Medical College, Gansu University of Chinese Medicine, Gansu Province, Lanzhou 730000, China；
2.Department of Gastroenterology, Gansu Provincial People’s Hospital, Gansu Province, Lanzhou 730000, China
|
|
|
|
Abstract Non-alcoholic fatty liver disease is one of the common chronic liver diseases in the world, and its incidence is on the rise in China. At present, its pathogenesis is not clear, but it is widely involved in liver glucose, lipid metabolism, insulin resistance, oxidative stress, and so on. Recent studies have found that skeletal muscle can affect non-alcoholic fatty liver disease by releasing muscle factors such as irisin, fibroblast growth factor-21, insulin-like growth factor-1, interleukin-6, tumor necrosis factor-α, and vascular endothelial growth factor B. In this paper, the correlation between some common muscle factors and non-alcoholic fatty liver disease and the possible mechanism of action in this disease are reviewed in order to provide a new perspective and thinking for the prevention and treatment of non-alcoholic liver disease.
|
|
|
|
|
|
[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018更新版）[J].中华肝脏病杂志，2018，34（5）：641-649.
[2] Zhou J，Zhou F，Wang W，et al. Epidemiological Features of NAFLD From 1999 to 2018 in China [J]. Hepatology，2020， 71（5）：1851-1864.
[3] Buzzetti E，Pinzani M，Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease（NAFLD）[J]. Metabolism，2016，65（8）：1038-1048.
[4] Das DK，Graham ZA，Cardozo CP. Myokines in skeletal muscle physiology and metabolism：Recent advances and future perspectives [J]. Acta Physiol（Oxf），2020，228（2）：e13367.
[5] Bostr?觟m P，Wu J，Jedrychowski MP，et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis [J]. Nature，2012，481（7382）：463-468.
[6] Hu J，Ke Y，Wu F，et al. Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease：A Systematic Review and Meta-Analysis [J]. Gastroenterol Res Pract，2020，2020：8818191.
[7] Monserrat-Mesquida M，Quetglas-Llabres M，Abbate M，et al. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease [J]. Antioxidants（Basel），2020，9（8）：759.
[8] Armandi A，Rosso C，Nicolosi A，et al. Crosstalk between Irisin Levels，Liver Fibrogenesis and Liver Damage in Non-Obese，Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease [J]. J Clin Med，2022，11（3）：635.
[9] Rahmanabadi A，Mahboob S，Amirkhizi F，et al. Oral alpha- lipoic acid supplementation in patients with non-alcoholic fatty liver disease：effects on adipokines and liver histology features [J]. Food Funct，2019，10（8）：4941-4952.
[10] Liu TY，Shi CX，Gao R，et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/ Akt pathway in type 2 diabetic mice and hepatocytes [J]. Clin Sci（Lond），2015，129（10）：839-850.
[11] Tang H，Yu R，Liu S，et al. Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling [J]. EBioMed- icine，2016，6：139-148.
[12] Zhu W，Sahar NE，Javaid HMA，et al. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Co- mpetitive Binding with MD2 [J]. Cells，2021，10（12）：3306.
[13] Liao X，Zhan W，Li R，et al. Irisin ameliorates endoplasmic reticulum stress and liver fibrosis through inhibiting PERK- mediated destabilization of HNRNPA1 in hepatic stellate cells [J]. Biol Chem ，2021，402（6）：703-715.
[14] Mo L，Shen J，Liu Q，et al. Irisin Is Regulated by CAR in Liver and Is a Mediator of Hepatic Glucose and Lipid Metabolism [J]. Mol Endocrinol，2016，30（5）：533-542.
[15] Hamrick MW. A role for myokines in muscle-bone interactions [J]. Exerc Sport Sci Rev，2011，39（1）：43-47.
[16] Yao Y，Miao X，Zhu D，et al. Insulin-like growth factor-1 and non-alcoholic fatty liver disease：a systemic review and meta-analysis [J]. Endocrine，2019，65（2）：227-237.
[17] Dichtel LE，Corey KE，Misdraji J，et al. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease [J]. Clin Transl Gastroenterol，2017，8（1）：e217.
[18] Yuan XX，Zhu HJ，Pan H，et al. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients [J]. World J Gastroenterol，2019，25（14）：1741- 1752.
[19] Cabrera D，Cabello-Verrugio C，Solis N，et al. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease：Beneficial Hepatic and Systemic Effects of Hormone Supplementation [J]. Int J Mol Sci，2018，19（5）：1339.
[20] Dong XC. FOXO transcription factors in non-alcoholic fatty liver disease [J]. Liver Res，2017，1（3）：168-173.
[21] Hribal ML，Procopio T，Petta S，et al. Insulin-like growth factor-I，inflammatory proteins，and fibrosis in subjects with nonalcoholic fatty liver disease [J]. J Clin Endocrinol Metab， 2013，98（2）：E304-E308.
[22] Seo DY，Park SH，Marquez J，et al. Hepatokines as a Mol- ecular Transducer of Exercise [J]. J Clin Med，2021，10（3）： 385.
[23] Waluga M，Kukla M，Zorniak M，et al. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease [J]. J Physiol Pharmacol，2017，68（3）：363- 374.
[24] Liu X，Zhang P，Martin RC，et al. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice [J]. Am J Cancer Res，2016，6（5）：1011-1025.
[25] Rusli F，Deelen J，Andriyani E，et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice [J]. Sci Rep，2016，6：30484.
[26] Keinicke H，Sun G，Mentzel CMJ，et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation [J]. Endocr Connect，2020，9（8）：755-768.
[27] Park JG，Xu X，Cho S，et al. CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis [J]. Sci Rep，2016，6：27938.
[28] Qiang W，Shen T，Noman M，et al. Fibroblast Growth Factor 21 Augments Autophagy and Reduces Apoptosis in Damaged Liver to Improve Tissue Regeneration in Zebrafish [J]. Front Cell Dev Biol，2021，9：756743.
[29] Lee JH，Kang YE，Chang JY，et al. An engineered FGF21 variant，LY2405319，can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function [J]. Am J Transl Res，2016，8（11）：4750-4763.
[30] Harrison SA，Rinella ME，Abdelmalek MF，et al. NGM282 for treatment of non-alcoholic steatohepatitis：a multicentre，randomised，double-blind，placebo-controlled，phase 2 trial [J]. Lancet，2018，391（10126）：1174-1185.
[31] Pedersen BK，Febbraio MA. Muscle as an endocrine organ：focus on muscle-derived interleukin-6 [J]. Physiol Rev，2008，88（4）：1379-1406.
[32] Jorge ASB，Andrade JMO，Paraiso AF，et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class Ⅲ obesity [J]. Obes Res Clin Pract，2018，12（2）：1-8.
[33] Goyale A，Jain A，Smith C，et al. Assessment of non-alcoholic fatty liver disease（NAFLD）severity with novel serum- based markers：A pilot study [J]. PloS One，2021，16（11）：e0260313.
[34] Skuratovskaia D，Komar A，Vulf M，et al. IL-6 Reduces Mitochondrial Replication，and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes [J]. Int J Mol Sci，2021，22（4）：1774.
[35] Ou R，Liu J，Lv M，et al. Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice [J]. Endocrine，2017，57（1）：72-82.
[36] Dembek A，Laggai S，Kessler SM，et al. Hepatic interleukin-6 production is maintained during endotoxin tolerance and facilitates lipid accumulation [J]. Immunobiology，2017，222（6）：786-796.
[37] Li L，Huang C，Yin H，et al. Interleukin-6 mediated exercise-induced alleviation of adiposity and hepatic steatosis in mice [J]. BMJ Open Diabetes Res Care，2021，9（1）：e001431.
[38] Li S，Chen L，Lv G. Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease：Indications From Mendelian Randomization [J]. Front Pharmacol，2022，13：905936.
[39] Chen Y，Ma K. NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease [J]. Biochem Biophys Res Commun，2019，511（3）：524-530.
[40] Ye X，Kong W，Zafar MI，et al. Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [J]. EXCLI J，2020，19：1186-1195. |
|
|
|
